Intraoperative Detection of Residual Cancer in Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

234

Participants

Timeline

Start Date

February 6, 2018

Primary Completion Date

April 10, 2020

Study Completion Date

April 10, 2020

Conditions
Breast Cancer
Interventions
COMBINATION_PRODUCT

LUM Imaging System

Drug: LUM015 Device: LUM 2.6 Imaging Device

Trial Locations (16)

17033

Penn State Hershey Medical Center, Hershey

27103

Novant Health, Winston-Salem

27710

Duke University Medical Center, Durham

32207

Baptist MD Anderson Cancer Physicians, Jacksonville

33756

Comprehensive Breast Care Center, Clearwater

36604

University of South Alabama, Mobile

44195

Cleveland Clinic, Cleveland

48073

Beaumont Royal Oak, Royal Oak

48098

Beaumont Troy, Troy

75231

Dallas Breast Center, Dallas

77030

MD Anderson Cancer Center, Houston

94304

Stanford University Medical Center, Palo Alto

98405

Franciscan Breast Surgery, Tacoma

06511

Yale University School of Medicine, New Haven

02114

Massachusetts General Hospital, Boston

01805

Lahey Hospital and Medical Center, Burlington

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Lumicell, Inc.

INDUSTRY